CG Oncology, Inc. (CGON) stock
CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$80.00+1.06 (+1.34%)
Close on Nov 18, 2026Market cap $7.09BP/E –Yield –
CG Oncology revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
CG Oncology's revenue for the twelve months ending Sep 30, 2026 was $6.17M, up 183.6% year over year. For fiscal 2025 it was $4.04M, up 254.7% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.04M | +254.7% |
| FY2024 | Dec 31, 2024 | $1.14M | +458.3% |
| FY2023 | Dec 31, 2023 | $204.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.60M | -3.7% |
| Q2 FY2026 | Jun 30, 2026 | $1.16M | – |
| Q1 FY2026 | Mar 31, 2026 | $1.08M | +1982.7% |
| Q4 FY2025 | Dec 31, 2025 | $2.32M | +409.2% |
| Q3 FY2025 | Sep 30, 2025 | $1.67M | +3774.4% |
| Q2 FY2025 | Jun 30, 2025 | $0 | -100.0% |
| Q1 FY2025 | Mar 31, 2025 | $52.00K | -90.2% |
| Q4 FY2024 | Dec 31, 2024 | $456.00K | +45500.0% |
| Q3 FY2024 | Sep 30, 2024 | $43.00K | +377.8% |
| Q2 FY2024 | Jun 30, 2024 | $111.00K | – |
| Q1 FY2024 | Mar 31, 2024 | $529.00K | +172.7% |
| Q4 FY2023 | Dec 31, 2023 | $1.00K | – |
| Q3 FY2023 | Sep 30, 2023 | $9.00K | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
| Q1 FY2023 | Mar 31, 2023 | $194.00K | – |
See a number that looks wrong?